Seattle Genetics, Merck partner on 2 oncology drug programs

By The Science Advisory Board staff writers

September 14, 2020 -- Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate (ADC). Separately, Seattle Genetics has granted Merck an exclusive license to commercialize a small-molecule drug for treatment of HER2-positive cancers.

Together, the companies will develop and commercialize ladiratuzumab vedotin, an investigational ADC targeting LIV-1, which is in phase II clinical trials for breast cancer and other solid tumors. Joint development will evaluate the ADC as a monotherapy and in combination with Keytruda, Merck's anti-PD-1 therapy, in triple-negative breast cancer and other solid tumors.

Seattle Genetics will receive a $600 million upfront payment and Merck will make a $1 billion equity investment in 5 million shares of Seattle Genetics at a price of $200 per share. Seattle Genetics will also be eligible for progress-dependent milestone payments of up to $2.6 billion.

Merck will commercialize tucatinib (Tukysa), a small-molecule tyrosine kinase inhibitor for the treatment of HER2-positive cancers, in Asia, the Middle East, and Latin America and other regions outside of the U.S., Canada, and Europe. Seattle Genetics will receive an upfront payment of $125 million from Merck and is eligible for progress-dependent milestones of up to $65 million. Merck will also co-fund global development efforts, including several ongoing and planned clinical trials. Seattle Genetics will continue to lead these projects.

Biopharma CEOs pledge commitment to safe vaccines
The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward...
Zymeworks, Merck to develop multispecific antibodies
Merck has signed a research and licensing agreement to develop multispecific antibody therapeutic candidates using platforms from clinical-stage biopharmaceutical...
Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.
IAVI, Merck partner on SARS-CoV-2 vaccine
Merck and IAVI, a nonprofit scientific research organization, announced that they are partnering to develop a recombinant vesicular stomatitis virus vaccine...
Serimmune, Merck reach drug discovery milestone
Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter